• Comparison of Anyu Peibo With Placebo in Treatment of MDD

  NCT02380066

  CompletedInterventionalPhase 2Updated Jan 2, 2020
• Comparison of Orcinoside With Placebo in Treatment of MDD

  NCT02191384

  CompletedInterventionalPhase 2Updated Sep 23, 2021
• Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb

  NCT03183505

  CompletedInterventionalPhase 2Updated Jan 23, 2019
• A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules

  NCT06749470

  Not yet recruitingInterventionalPhase 4Updated Dec 27, 2024
• Comparison of Anyu Peibo With Placebo in Treatment of MDD in China

  NCT04210973

  Unknown statusInterventionalPhase 3Updated May 12, 2020
• Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

  NCT06828887

  RecruitingInterventionalPhase 2Updated May 20, 2026

ClinicalTrials.gov ID

NCT02395263

Lead Sponsor

Shanghai Mental Health CenterOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 2

Enrollment

160Estimated

Last Update Posted

Mar 24, 2015Estimated

Start Date

Mar 2015

Primary Completion Date

Mar 2016Estimated

Completion Date

Apr 2016Estimated

Official Title

Proof Of Concept Study of Yuxintine in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial

Brief Summary

The purpose of this study is to determine whether Yuxintine Capsule in different doses are effective in the treatment of Depression.

And to explore the preliminary information of safety and efficacy of Yuxintine Capsule in the Chinese Patients with Depression.

• Major Depressive Disorder (MDD)

• Yuxintine

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria of DSM-IV-TR, single episode or recurrent episode, not accompanied with psychotic symptoms. Coding of diagnosis included: 296.2 and 296.3.
• The Subject with Heart-Spleen Deficiency based on the CTM.
• The total score of MADRS is ≥22 in both screening visit and baseline visit.
• The total score of HAMD-17 is ≥18 and ≤30, AND item 1 ≥2 in both screening visit and baseline visit.
• The subject understands and consents to takes part in this clinical trials. The subjects should sign informed consent.

Exclusion Criteria:

• The subject made a suicide attempt in recent 6 months or has a score ≥3 on item 3(suicide assessment) of the HAMD.
• The subject has a current DSM-Ⅳ-TR axisⅠpsychiatric diagnosis other than depression.
• When the MADRS score of baseline visit compares with the screening visit, the decreasing rate is ≥25%.
• Any unstable cardiovascular, hepatic, renal, endocrine(thyroid gland dysfunction), blood(e.g. bleeding tendency),or other medical disease.
• Had a history of seizure disorder,except infantile febrile convulsion.
• The subject has accepted psychosurgery or electroconvulsive therapy within 3 months.
• With psychotic symptoms.
• The subject has a history of mania episode, including manic, mixed or rapid cycle attack.
• The subject has a current diagnosis or history of depression due to any other psychotic disorder or a general medical condition.
• The subject with refractory depressive disorder,i.e.the patients who used at least two different mechanisms antidepressants with adequate dosage and duration treatment still had no respond.
• Clinically significant electrocardiographic(ECG) abnormalities or abnormal laboratory values(eg. Hepatic function above 1.5 times of clinical toplimit, renal function index above toplimit, abnormal coagulation function and clinical significance of abnormality, i.e. Prothrombin time shorten or extend more than 3 seconds or a dynamic variation or APTT prolonged more than 10 seconds,AND fibrinogen L or been progressive decline, or > 4.0 g/L).
• The subject has a diagnosis of alcohol or other substance abuse or dependence at least 1 years prior to the baseline visit.
• Known hypersensitivity to Ginseng, or at least to two kinds of drugs, or serious allergic physique.
• Women who were pregnant, breast-feeding, or planning to become pregnant during study. Men who have request to fertility during study period. The subject could not take safe and effective birth control measures.
• The subject could not take medication according to the doctor's advice.
• The subject uses antidepressant drug normally before 2 weeks of screening, and stops using psychotropic drug less than 7 half-life period (monoamine oxidase inhibitor more than 2 weeks).
• The subject has participated in a drug clinical trial within 3 months before screening.
• The investigator think the subject is unsuitable to enrol in this clinical trial.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Shanghai Mental Health CenterOTHER

Collaborators

Shanghai Innovative Research Center of Traditional Chinese MedicineOTHER

liuyuanliyuxin@126.com13931292966

1945461929@qq.com13808431145